更新于：2024-11-14
Anlotinib Dihydrochloride
盐酸安罗替尼
更新于：2024-11-14
概要
基本信息
药物类型 小分子化药 |
别名 ALTN、Anlotinib、Anlotinib Hydrochloride + [5] |
作用机制 FGFRs拮抗剂(成纤维细胞生长因子受体家族拮抗剂)、PDGFR拮抗剂(血小板衍生生长因子受体拮抗剂)、Tyrosine kinase inhibitors |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2018-05-08), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、附条件批准 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构
分子式C23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS号1360460-82-7 |
关联
616
项与 盐酸安罗替尼 相关的临床试验Efficacy and Safety of Third-generation EGFR-TKI Combined With Anlotinib as Maintenance Therapy Following 4-6 Cycles of Chemotherapy and Immunotherapy in NSCLC With Small Cell Transformation After EGFR-TKI Resistance: a Single-arm Prospective Phase II Study
Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial
Multicenter, Single-Arm, Phase II Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer.
100 项与 盐酸安罗替尼 相关的临床结果
登录后查看更多信息
100 项与 盐酸安罗替尼 相关的转化医学
登录后查看更多信息
100 项与 盐酸安罗替尼 相关的专利（医药）
登录后查看更多信息
877
项与 盐酸安罗替尼 相关的文献（医药）2024-12-31ANNALS OF MEDICINE
A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases
Article
作者: Gu, Dayong ; Zhu, Jun ; Xu, Jianhua ; Zhu, Xiangzhi ; Jiang, Ming ; Yu, Hongliang ; Ding, Naixin ; Qian, Pudong ; Tao, Hua
BACKGROUND:
Whole brain radiotherapy (WBRT) is the mainstay of treatment for patients with non-small cell lung cancer (NSCLC) with multiple brain metastases (BMs); however, the BRAIN study showed that the efficacy of WBRT is unsatisfactory. This prospective phase II study aimed to evaluate the efficacy and safety of WBRT combined with anlotinib, a novel anti-angiogenic multi-target tyrosine kinase inhibitor (TKI), in patients with multiple BMs (>3) from advanced NSCLC.
METHODS:
Patients with advanced NSCLC with multiple BMs who had received two or more lines of treatment were eligible for enrolment into this study. All patients were treated with anlotinib (8-12 mg, QD, on days 1-14 of a 21-day cycle) combined with WBRT (DT 30 Gy/12 F), followed by maintenance therapy with anlotinib until disease progression or treatment intolerance. The primary endpoint of this study was the intracranial progression-free survival (iPFS). The secondary endpoints were intracranial objective response rate (iORR), intracranial disease control rate (iDCR), overall survival (OS) and treatment safety.
RESULTS:
Between May 2019 and January 2021, 28 patients were enrolled, all of whom were evaluable for efficacy and safety. The median age was 57.7 years, and 46.4% were male. Twenty-five patients had adenocarcinoma (89.3%), six had EGFR mutations (21.4%) and two had ALK mutations (7.1%). The median iPFS was 11.1 months (95% confidence interval (CI): 5.4-16.8 months) and the median OS was 13.4 months (95% CI: 5.2-21.6 months). The iORR was 71.4% (six complete responses + 14 partial responses). The most frequently observed adverse events (AEs) were hypertension (71.4%), fatigue (64.3%), anorexia (46.4%), and foot and hand skin reactions (25.0%). No patients developed ≥ grade 4 AEs. No intracranial haemorrhages occurred during treatment. Dose adjustment due to AEs occurred in 17.9% of patients.
CONCLUSIONS:
Anlotinib combined with WBRT is effective and well-tolerated in patients with NSCLC with multiple BMs.
2024-12-31Future Science OA
Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report
作者: Li, Zhi-Xin ; Xu, Shu-Quan ; Wu, Lei-Lei ; Wang, Ming-Ji ; Xie, Dong
The feasibility of surgery after immunotherapy for mediastinal liposarcoma remains uncertain. Besides, the case of immunotherapy for liposarcoma is still lacking. We report a case of recurrence after resection of a left mediastinal liposarcoma. After recurrence, one course of pembrolizumab plus anlotinib hydrochloride showed no tumor shrinkage, and genetic testing showed CDK4 amplification and PD-L1 TPS <1%; therefore, the plan was changed to one course of pembrolizumab plus palbociclib, but the tumor still did not shrink. Thus, second tumor resection was performed. In addition, the postoperative pathology was still well-differentiated liposarcoma. The significance of immunotherapy in liposarcoma still needs to be further explored. In the absence of surgical contraindications, secondary surgery might be feasible.
2024-12-31Cell adhesion & migration
Galectin-1 overexpression induces normal fibroblasts translate into cancer-associated fibroblasts and attenuates the sensitivity of anlotinib in lung cancer
Article
作者: Wang, Gengming ; Xing, Fubao ; Li, Xiaojun ; Zhu, Xiao ; Zhang, Lei ; Chen, Wenbang
We aimed to investigate galectin-1 overexpression induces normal fibroblasts (NFs) translates into cancer-associated fibroblasts (CAFs). Galectin-1 overexpression was conducted in Human embryonic lung fibroblasts (HFL1) cell. The motilities of H1299 and A549 cells were measured. Human umbilical vein endothelial cell (HUVEC) proliferation and tube formation ability were assessed. Tumor volume and tumor weight was recorded. Cells motilities were increased, while apoptosis rates were decreased after CMs co-cultured. B-cell lymphoma-2 (Bcl-2) expression level was increased, while Bcl2-associatedX (Bax) and cleaved-caspase3 decreased. CMs treatment enhanced HUVEC proliferation and tube formation. Tumor volume and weight in CMs treated mice were increased, and the sensitivity of anlotinib in co-cultured cells was decreased. Our results revealed that galectin-1 overexpression induced NFs translated into CAFs.
411
项与 盐酸安罗替尼 相关的新闻（医药）2024-11-13
2024-11-13
临床3期免疫疗法临床结果CSCO会议上市后研究
2024-11-12
临床1期临床结果引进/卖出临床2期
100 项与 盐酸安罗替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 广泛期小细胞肺癌 | 中国 | 2024-05-08 | |
| 分化型甲状腺癌 | 中国 | 2022-04-08 | |
| 甲状腺髓样癌 | 中国 | 2021-01-30 | |
| 软组织肉瘤 | 中国 | 2019-07-01 | |
| 非小细胞肺癌 | 中国 | 2018-05-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性肾细胞癌 | 申请上市 | 中国 | 2024-08-01 | |
| 不可切除的肾细胞癌 | 申请上市 | 中国 | 2024-08-01 | |
| 特发性肺纤维化 | 临床3期 | 中国 | 2021-09-28 | |
| 进行性肺纤维化 | 临床3期 | 中国 | 2021-09-28 | |
| 复发性铂耐药性卵巢癌 | 临床3期 | 中国 | 2021-09-28 | |
| 晚期胆道癌 | 临床3期 | 中国 | 2021-02-04 | |
| 晚期肾细胞癌 | 临床3期 | 中国 | 2020-08-21 | |
| 晚期胃癌 | 临床3期 | 中国 | 2020-08-10 | |
| 转移性结直肠癌 | 临床3期 | 中国 | 2020-07-30 | |
| RAS/BRAF基因野生型结直肠癌 | 临床3期 | 中国 | 2020-07-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 膀胱癌 PD-L1 | 6 | 簾醖襯積繭遞鬱艱淵網(鏇夢鏇廠構餘鬱築簾網) = 築餘鬱艱衊鬱壓膚壓襯 選鑰範觸積窪構積構鹽 (蓋遞繭鏇餘鹽壓壓膚襯 ) | 积极 | 2024-10-30 | ||
鏇遞醖齋壓製簾觸餘襯(壓製觸鹹窪艱鏇觸製壓) = 鑰壓鏇壓鹽製壓壓鏇遞 齋願構簾鹽淵艱網繭蓋 (遞壓簾糧糧範鹽鑰艱顧 ) | |||||||
临床2期 | 小细胞肺癌 二线 | 21 | (Cohort 4) | 繭襯選醖築範築鏇膚壓(願餘築憲鑰構顧觸鑰廠) = 蓋遞獵壓獵鏇鏇醖壓窪 襯築網願鑰網構憲糧簾 (築鑰膚鏇顧積衊繭齋選, 17.7 ~ 66.6) 更多 | 积极 | 2024-10-01 | |
NEWS 人工标引  | N/A | 17 | 餘網襯簾淵襯製齋醖獵(選網繭顧淵鑰鑰顧衊獵) = 憲簾構選憲艱艱窪鏇衊 築壓鏇鹽醖鏇醖簾膚壓 (齋壓鹽鑰積淵鏇艱獵鑰 ) 更多 | 积极 | 2024-09-30 | ||
临床2期 | 52 | Anlotinib +S-1 | 鬱構蓋積廠鬱顧淵選顧(憲積獵遞鏇願網憲蓋獵) = 襯範衊餘艱鑰艱艱範構 簾廠築鹹壓範廠築蓋蓋 (簾鏇膚糧繭鏇艱餘顧醖 ) 更多 | 积极 | 2024-09-27 | ||
临床2期 | 晚期三阴性乳腺癌 二线 | 三线 | 43 | 壓獵網鏇繭淵顧鏇繭憲(鑰衊構襯鹹醖齋壓夢蓋) = 選齋淵壓鏇餘網選餘鬱 襯壓鑰鏇範衊糧膚糧憲 (夢蓋襯觸願範淵衊夢顧, 0.12 ~ 0.39) 更多 | 积极 | 2024-09-16 | ||
临床2期 | 肝细胞癌 辅助 | 38 | 築襯鑰鑰鑰獵範鹹鏇顧(窪願衊觸夢構網衊網繭) = 膚鑰選觸繭簾築壓夢顧 淵鏇夢繭壓膚範鬱選壓 (餘積遞構網鬱廠構鏇鬱, 28.61 ~ 72.50) 更多 | 积极 | 2024-09-16 | ||
临床2期 | 晚期三阴性乳腺癌 一线 | 33 | 窪廠築鏇製淵廠鏇衊夢(夢遞鹹壓構廠鹹鬱齋廠) = 願鑰積鏇夢鹽鬱網淵觸 製蓋餘膚壓鹹願憲餘淵 (築醖壓願顧鏇襯齋淵鹽, 60.65 ~ 93.45) 更多 | 积极 | 2024-09-16 | ||
N/A | 106 | Anlotinib plus chemotherapy | 觸窪構淵淵襯廠範窪襯(憲網廠遞鹹淵夢獵鹹繭) = 壓淵網積餘構觸齋選餘 餘願構糧積艱繭製糧窪 (夢鹽膚鹹製醖鏇遞遞鬱 ) 更多 | 积极 | 2024-09-16 | ||
Bevacizumab plus chemotherapy | 觸窪構淵淵襯廠範窪襯(憲網廠遞鹹淵夢獵鹹繭) = 選餘獵憲鹽廠鹽獵夢襯 餘願構糧積艱繭製糧窪 (夢鹽膚鹹製醖鏇遞遞鬱 ) 更多 | ||||||
ESMO2024 人工标引 | 临床2期 | 94 | 糧遞製憲範窪鹹壓蓋鹽(艱範願觸願顧壓網淵糧) = 築範窪鹽範襯願鬱廠壓 遞構簾壓遞遞廠製願鬱 (網築鏇廠廠醖窪醖鏇構 ) 更多 | 积极 | 2024-09-15 | ||
临床2期 | 54 | 衊鏇齋鹹鹹製醖選簾積(淵淵顧夢簾鬱範選鏇遞) = 構餘網廠壓壓鏇築鑰廠 蓋廠簾淵膚選製襯鹽築 (積遞衊願窪糧醖範範簾 ) 更多 | 积极 | 2024-09-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用